Improvement in patient‐reported "taste" and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials.

In conclusion, our analysis shows that in patients with severe CRSwNP, dupilumab treatment improved patient-reported "taste" versus placebo. Sense of smell was measured using the loss-of-smell score (LoS) - reported daily by patients on a scale of 0-3, similar to how patient-reported taste was measured - UPSIT and the SNOT-22 smell/taste item. Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials Post-hoc analysis showed dupilumab significantly improves patient-reported "taste" versus placebo in patients with severe CRSwNP. [Extracted from the article]